Newer treatments of psoriasis regarding IL‐23 inhibitors,phosphodiesterase 4 inhibitors,and Janus kinase inhibitors |
| |
| Authors: | Dominika Wcisło‐Dziadecka Martyna Zbiciak‐Nylec Ligia Brzezińska‐Wcisło Katarzyna Bebenek Agata Kaźmierczak |
| |
| Affiliation: | 1. Department of Skin Structural Studies, Chair of Cosmetology, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Poland;2. Department of Dermatology, Andrzej Miel?cki Memorial Independent Public Clinical Hospital in Katowice, Poland;3. Chair and Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, Poland;4. School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland;5. STN Students Association by Department of Skin Structural Studies, Medical University of Silesia, Sosnowiec, Poland |
| |
| Abstract: | The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL‐23 inhibitors are now in phase III of clinical trials. The aim of the action of both drugs is selective IL‐23 inhibition by targeting the p19 subunit. Guselkumab is a fully human monoclonal antibody. Tildrakizumab is a humanized monoclonal antibody, which also belongs to IgG class and is targeted to subunit p19 of interleukin 23 (IL‐23). Phosphodiesterase inhibitors exert an anti‐inflammatory action and their most common group is the PDE4 family. PDE4 inhibits cAMP, which reduces the inflammatory response of the pathway of Th helper lymphocytes, Th17, and type 1 interferon which modulates the production of anti‐inflammatory cytokines such as IL‐10 interleukins. The Janus kinase (JAK) signaling pathway plays an important role in the immunopathogenesis of psoriasis. Tofacitinib suppresses the expression of IL‐23, IL‐17A, IL‐17F, and IL‐22 receptors during the stimulation of lymphocytes. Ruxolitinib is a selective inhibitor of JAK1 and JAK2 kinases and the JAK‐STAT signaling pathway. This article is a review of the aforementioned drugs as described in the latest available literature. |
| |
| Keywords: | biological drugs IL‐23 inhibitors immune‐modulating JAK inhibitors PDE4 inhibitors psoriasis therapy treatment |
|
|
